Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A

Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms

(2011) Anthony Harrison et al.   XENOBIOTICA

Impact of microdosing clinical study — Why necessary and how useful?

(2010) Yuichi Sugiyama et al.   ADVANCED DRUG DELIVERY REVIEWS

Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP1 receptor antagonist for the treatment of inflammatory pain

(2009) Adrian Hall et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Early human studies of investigational agents: dose or microdose?

(2009) Lionel D. Lewis   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A pharmacokinetic evaluation of five H1antagonists after an oral and intravenous microdose to human subjects

(2009) Ajay Madan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Microdose Clinical Trial: Quantitative Determination of Nicardipine and Prediction of Metabolites in Human Plasma

(2009) Naoe Yamane et al.   Drug Metabolism and Pharmacokinetics

Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge

(2009) Robert MJ Ings   Bioanalysis

Discovery of GSK345931A: An EP1 receptor antagonist with efficacy in preclinical models of inflammatory pain

(2008) Adrian Hall et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The utility of microdosing over the past 5 years

(2008) Graham Lappin et al.   Expert Opinion on Drug Metabolism & Toxicology

Microsomal Prostaglandin E2Synthase-1 (mPGES-1): A Novel Anti-Inflammatory Therapeutic Target

(2008) Richard W. Friesen et al.   JOURNAL OF MEDICINAL CHEMISTRY

MF63 [2-(6-Chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of Inflammation

(2008) D. Xu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS